To date, two CD19-specific chimeric antigen receptor (CAR)-T cell therapies for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL) have been approved (June and Sadelain, 2018). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.